Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is utilizing the combined capabilities of AI with its extensive database of tumor data to assist clinicians in selecting the most effective drug treatments for cancer patients. An article discussing the company reads, “One disruptive aspect of POAI’s technology is that it helps the clinician to increase the chance of choosing more effective therapy, resulting in potential reduction of side-effects as well as cost savings. Traditionally oncologists prescribe what drugs they think have the best chance at beating a patient’s cancer, and the drug may or may not prove effective. Meanwhile, the patient’s undergoes chemotherapy with often debilitating side effects. If the drug proves to be a poor fit for the patient’s cancer, the chemotherapy experience will have been in vain, and the patient must continue acting as a guinea pig in experimenting with the next likely drug candidate. This is the standard cancer treatment of today. However, by utilizing POAI’s innovative tumor-profiling platform, which literally performs chemotherapy on the patient’s tumor outside the body to determine which drug is most effective, the patient can be spared many of the risks of being a ‘guinea-pig’ as the oncologist attempts different drugs.”
To view the full article, visit http://ibn.fm/8jAr5
About Predictive Oncology Inc.
Predictive Oncology is an AI-driven company focused on applying artificial intelligence to personalized medicine and drug discovery. The company applies smart tumor profiling and its AI platform to extensive genomic and biomarker patient data sets to predict clinical outcomes and, most importantly, improve patient outcomes for cancer patients of today and tomorrow. Predictive Oncology currently has approximately 150,000 clinically validated cases on its molecular information platform, with more than 38,000 specific to ovarian cancer. The company’s data is highly differentiated, having both drug-response data and access to historical outcome data from patients. Predictive Oncology intends to generate additional sequence data from these tumor samples to deliver on the clear unmet market need across the pharmaceutical industry for a multi-omic approach to new drug development. For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.